TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7802305

Group type: EXPERIMENTAL
Intervention: PCEA with sufentanil and concomitant infusion of sufentanil
Number of subjects: 40

Group type: COMPARATOR
Intervention: PCEA with sufentanil and concomitant infusion of saline (control)
Number of subjects: 40
Study: 2334617

Group type: EXPERIMENTAL
Intervention: Local analgesia (retrobulbar block)
Number of subjects: 18

Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 18
Study: 380630

Group type: EXPERIMENTAL
Intervention: Multiple intradermal injections of absolute alcohol
Number of subjects: 17

Group type: COMPARATOR
Intervention: Water injections (control)
Number of subjects: 17
Study: 31812227

Group type: EXPERIMENTAL
Intervention: COL1A1 (collagen α‐1(I) chain)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: BMP‐6 (bone morphogenetic protein‐6)
Number of subjects: 1007

Group type: EXPERIMENTAL
Intervention: IL‐6Rα (interleukin‐6 receptor α chain)
Number of subjects: 1007

Group type: COMPARATOR
Intervention: Low COL1A1, low BMP‐6, and high IL‐6Rα levels
Number of subjects: 1007
Study: 31778193

Group type: EXPERIMENTAL
Intervention: Personal hygiene strategies for SSTI prevention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S. aureus vaccine trial (Phase 2)
Number of subjects: 0
Study: 27964769

Group type: EXPERIMENTAL
Intervention: Educational review session
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Aide-memoir
Number of subjects: 292

Group type: EXPERIMENTAL
Intervention: Both educational review and aide-memoir
Number of subjects: 292

Group type: COMPARATOR
Intervention: Non-intervention control group
Number of subjects: 292
Study: 26027431

Group type: EXPERIMENTAL
Intervention: Nivolumab plus Ipilimumab
Number of subjects: 945

Group type: COMPARATOR
Intervention: Ipilimumab
Number of subjects: 945

Group type: COMPARATOR
Intervention: Nivolumab
Number of subjects: 945
Study: 24140184

Group type: EXPERIMENTAL
Intervention: Axitinib titration (5 mg twice daily during a 4 week lead-in, then titrated to 7 mg and 10 mg if tolerated)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo titration
Number of subjects: 213

Group type: COMPARATOR
Intervention: Non-randomised group (no titration)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Axitinib titration
Number of subjects: 213

Group type: COMPARATOR
Intervention: Non-randomised group
Number of subjects: 213
Study: 21902287

Group type: EXPERIMENTAL
Intervention: Intravenous morphine combined with naltrexone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous morphine alone
Number of subjects: 0
Study: 19696703

Group type: EXPERIMENTAL
Intervention: Single-step sclerotomy
Number of subjects: 12

Group type: COMPARATOR
Intervention: Two-step sclerotomy
Number of subjects: 12
Study: 17941363

Group type: EXPERIMENTAL
Intervention: Soy moisturizer containing nondenaturated STI and BBI
Number of subjects: 65

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 65
Study: 15483463

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir DF) 300 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (tenofovir DF)
Number of subjects: 0
Study: 11696966

Group type: EXPERIMENTAL
Intervention: Mapping-enhanced counseling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard counseling
Number of subjects: 0
Study: 9817605

Group type: EXPERIMENTAL
Intervention: Felodipine-metoprolol (Logimax®)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study: 8164053

Group type: EXPERIMENTAL
Intervention: Tamoxifen 30 mg/d for 2 years
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 6731771

Group type: EXPERIMENTAL
Intervention: Fast-dissolving oral preparation of oxazepam, administered at least one hour pre-operatively
Number of subjects: 0
Study: 31733783

Group type: EXPERIMENTAL
Intervention: Maitland's postero‐anterior (PA glide) mobilization
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Mulligan's sustained natural apophyseal glide (SNAG)
Number of subjects: 33
Study: 30196031

Group type: EXPERIMENTAL
Intervention: No axillary dissection
Number of subjects: 934

Group type: COMPARATOR
Intervention: Axillary dissection
Number of subjects: 934
Study: 27212429

Group type: COMPARATOR
Intervention: bOPV (3 doses)
Number of subjects: 939

Group type: COMPARATOR
Intervention: tOPV (3 doses)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: bOPV + 1 dose IPV
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: bOPV + 2 doses IPV
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: IPV (1 or 2 doses)
Number of subjects: 939
Study: 24184649

Group type: EXPERIMENTAL
Intervention: TLSO (Thoracolumbosacral Orthosis)
Number of subjects: 96

Group type: COMPARATOR
Intervention: No Orthosis (NO)
Number of subjects: 96
Study: 22304891

Group type: EXPERIMENTAL
Intervention: Suffocation script condition (CS+) with inhalation of 35% CO(2) as UCS
Number of subjects: 33

Group type: COMPARATOR
Intervention: Neutral script condition (CS-) with inhalation of room air
Number of subjects: 33

Group type: COMPARATOR
Intervention: Urgency script condition (CS-) with inhalation of room air
Number of subjects: 33
Study: 19357421

Group type: EXPERIMENTAL
Intervention: Internet intervention (n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Usual care (n = 10)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Internet intervention
Number of subjects: 22
Study: 17606546

Group type: EXPERIMENTAL
Intervention: New diaper‐changing, hand‐washing, and food‐preparation equipment
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no new equipment, but received hygiene training)
Number of subjects: 46
Study: 18705977

Group type: EXPERIMENTAL
Intervention: High-intensity implementation strategy for intravenous thrombolysis
Number of subjects: 12

Group type: COMPARATOR
Intervention: Regular implementation strategy for intravenous thrombolysis
Number of subjects: 12
Study: 15304146

Group type: EXPERIMENTAL
Intervention: Quality circles intervention (11 sessions and repeated feedback on prescribing)
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Control group (no quality circles intervention)
Number of subjects: 100000
Study: 11068591

Group type: EXPERIMENTAL
Intervention: Accelerated fractionation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 0
Study: 8979328

Group type: EXPERIMENTAL
Intervention: Intraoperative autologous transfusion with hemodilution and apheresis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraoperative autologous transfusion alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional transfusion therapy (retrospective cohort)
Number of subjects: 0
Study: 1334284

Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 828

Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 828
Study: 3880993

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg/day
Number of subjects: 8
Study: 31403325

Group type: EXPERIMENTAL
Intervention: Primary probing only
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Primary probing with monocanalicular silastic stent intubation
Number of subjects: 102

Group type: COMPARATOR
Intervention: External dacryocystorhinostomy (for failure cases)
Number of subjects: 102
Study: 30595357

Group type: EXPERIMENTAL
Intervention: PCI with new-generation drug-eluting stents (DES)
Number of subjects: 3986

Group type: COMPARATOR
Intervention: CABG (historical DELTA-1 cohort)
Number of subjects: 3986
Study: 28971986

Group type: EXPERIMENTAL
Intervention: In-person counseling (IPC)
Number of subjects: 781

Group type: COMPARATOR
Intervention: Telephone counseling (TC)
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Cost barriers
Number of subjects: 781

Group type: EXPERIMENTAL
Intervention: Perceived comparative mutation risk
Number of subjects: 781
Study: 26541812

Group type: EXPERIMENTAL
Intervention: Cool Little Kids Online (intervention group)
Number of subjects: 385

Group type: COMPARATOR
Intervention: Delayed access (control group)
Number of subjects: 385
Study: 22450257

Group type: EXPERIMENTAL
Intervention: Plyometric Training Group (PTG)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 45
Study: 21414045

Group type: EXPERIMENTAL
Intervention: HVP (5-15 g per day)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Inulin (control)
Number of subjects: 59
Study: 19669067

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy (16 semi-structured sessions)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral group therapy
Number of subjects: 40
Study: 17301114

Group type: EXPERIMENTAL
Intervention: Parent Baby Interaction Programme (PBIP)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control
Number of subjects: 233
Study: 15557491

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (250 microg)
Number of subjects: 939

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (160 microg/m2)
Number of subjects: 939

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 939
Study: 11485143

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride (monotherapy) at doses of 1.5-4.5 g once daily or in two divided doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colesevelam hydrochloride combined with HMG-CoA reductase inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colesevelam hydrochloride (monotherapy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Colesevelam hydrochloride
Number of subjects: 0
Study: 8988911

Group type: EXPERIMENTAL
Intervention: MCT oil
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Palm oil
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High oleic acid sunflower oil
Number of subjects: 9
Study: 8097921

Group type: EXPERIMENTAL
Intervention: Abecarnil 20 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Abecarnil 40 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2880903

Group type: EXPERIMENTAL
Intervention: Chlorhexidine instillation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline instillation
Number of subjects: 0
Study: 29868998

Group type: EXPERIMENTAL
Intervention: Behavioral drug abuse treatment (intervention)
Number of subjects: 1305

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 1305
Study: 26682749

Group type: EXPERIMENTAL
Intervention: Vitamin D (800 IU/day) without exercise
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Placebo and exercise
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Vitamin D (800 IU/day) with exercise
Number of subjects: 409

Group type: COMPARATOR
Intervention: Placebo without exercise
Number of subjects: 409
Study: 22943586

Group type: EXPERIMENTAL
Intervention: Pulse lavage therapy at 10 to 15 psi pressure
Number of subjects: 30

Group type: COMPARATOR
Intervention: Moist betadine saline gauze dressings
Number of subjects: 30
Study: 22519907

Group type: EXPERIMENTAL
Intervention: Premeal cycling at moderate intensity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meal-only condition (control)
Number of subjects: 0
Study: 20533373

Group type: EXPERIMENTAL
Intervention: 0.8 mg rhFGF-2 (low-dosage group)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 2.4 mg rhFGF-2 (high-dosage group)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Low-dosage group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: High-dosage group
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 70
Study: 18535816

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 8
Study: 16422854

Group type: EXPERIMENTAL
Intervention: Sildenafil plus continuous testosterone undecanoate therapy (TRT) in group 1ST
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sildenafil alone in group 2S
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sildenafil plus continuous TRT for 2 months in group 2ST
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate therapy (TRT) alone in group 1T
Number of subjects: 40
Study: 12040138

Group type: EXPERIMENTAL
Intervention: Combined interventions
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Psychoeducational and psychotherapeutic interventions
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Interventions for dementia caregivers
Number of subjects: 78
Study: 9801742

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide aqueous pump spray (Rhinocort Aqua) 32 micrograms, 64 micrograms, 128 micrograms, 256 micrograms
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide aqueous pump spray (Rhinocort Aqua) 32 micrograms, 128 micrograms, 256 micrograms
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide aqueous pump spray (Rhinocort Aqua) 256 micrograms
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide aqueous pump spray (Rhinocort Aqua)
Number of subjects: 406
Study: 10155437

Group type: EXPERIMENTAL
Intervention: Actronics Interactive Learning System (IVD)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Traditional method of demonstration/return demonstration
Number of subjects: 86
Study: 2788116

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 180

Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 180
Study: 324723

Group type: EXPERIMENTAL
Intervention: sulphamethoxazole/trimethoprim (Bactrim)
Number of subjects: 30

Group type: COMPARATOR
Intervention: nitrofurantoin
Number of subjects: 30
Study: 30998643

Group type: EXPERIMENTAL
Intervention: Prominent cannulated screws
Number of subjects: 20

Group type: COMPARATOR
Intervention: Recessed cannulated screws
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 28813007

Group type: EXPERIMENTAL
Intervention: Probiotics formula containing Bifidobacterium longum BORI and Lactobacillus acidophilus AD031 (N = 28)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo (probiotic‐free skim milk, N = 29)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Probiotics formula
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 25972527

Group type: EXPERIMENTAL
Intervention: Epicatechin (100 mg/d)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Quercetin (160 mg/d)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 23585192

Group type: EXPERIMENTAL
Intervention: Normal weight (BMI <25 kg/m²)
Number of subjects: 3017

Group type: EXPERIMENTAL
Intervention: Overweight (BMI ≥25 kg/m² and <30 kg/m²)
Number of subjects: 3017

Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥30 kg/m²)
Number of subjects: 3017

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Number of subjects: 3017
Study: 20439105

Group type: EXPERIMENTAL
Intervention: 10-year cardiovascular risk assessment by practice nurses
Number of subjects: 421
Study: 19251200

Group type: EXPERIMENTAL
Intervention: PPTs ON
Number of subjects: 240

Group type: COMPARATOR
Intervention: PPTs OFF
Number of subjects: 240
Study: 16428266

Group type: EXPERIMENTAL
Intervention: H pylori eradication therapy (group 1, n = 41)
Number of subjects: 81

Group type: COMPARATOR
Intervention: No treatment (group 2, n = 40)
Number of subjects: 81
Study: 15387976

Group type: EXPERIMENTAL
Intervention: OAC(250) for 1 week (group A1)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: OAC(250) for 2 weeks (group A2)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: OAC(500) for 1 week (group B1)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: OAC(500) for 2 weeks (group B2)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: OAM for 1 week (group C1)
Number of subjects: 248

Group type: EXPERIMENTAL
Intervention: OAM for 2 weeks (group C2)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Successful Hp eradication
Number of subjects: 248

Group type: COMPARATOR
Intervention: Unsuccessful Hp eradication
Number of subjects: 248
Study: 11788000

Group type: EXPERIMENTAL
Intervention: Strand displacement amplification (SDA) in first‐catch urine (FCU) specimens from men
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Strand displacement amplification (SDA) in first‐catch urine (FCU) specimens from women
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Strand displacement amplification (SDA) in endocervical swab (ECS) specimens from women
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Ligase chain reaction (LCR)
Number of subjects: 1006
Study: 9373743

Group type: EXPERIMENTAL
Intervention: Communication course (4 weeks)
Number of subjects: 47

Group type: COMPARATOR
Intervention: No further rehabilitation (control group)
Number of subjects: 47
Study: 1348079

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha (1, 3, or 5 million units thrice weekly for 4 or 6 months)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha
Number of subjects: 12
Study: 3886998

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, coumadin, and dipyridamole for 18 months
Number of subjects: 59

Group type: COMPARATOR
Intervention: No specific therapy
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, coumadin, and dipyridamole
Number of subjects: 59
Study: 30650183

Group type: EXPERIMENTAL
Intervention: Compression Technique (CT)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Manual Technique (MT)
Number of subjects: 157
Study: 28733284

Group type: EXPERIMENTAL
Intervention: FM‐CBAL74 (fermented cow's milk containing heat-killed Lactobacillus paracasei CBA L74)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study: 26169336

Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Artemether-lumefantrine
Number of subjects: 150
Study: 23680059

Group type: EXPERIMENTAL
Intervention: Insulin (INS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (ROS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard strategy targeting HbA1c to 7.0%-7.9% (53-63mmol/mol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intensive control targeting HbA1c to <6.0% (42mmol/mol)
Number of subjects: 0
Study: 21646925

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 194
Study: 18312543

Group type: EXPERIMENTAL
Intervention: Tolterodine (4 mg daily for 6 days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 16550731

Group type: EXPERIMENTAL
Intervention: DOX GITS (4 mg/d)
Number of subjects: 310

Group type: COMPARATOR
Intervention: DOX-S4 (4 mg/d)
Number of subjects: 310

Group type: COMPARATOR
Intervention: DOX-S2 (2 mg/d)
Number of subjects: 310
Study: 12606887

Group type: EXPERIMENTAL
Intervention: Calcium carbonate (1200 mg of elemental calcium daily)
Number of subjects: 617

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 617
Study: 10960963

Group type: EXPERIMENTAL
Intervention: Exercise condition (50% maximal workload on the bicycle ergometer for four times 30 minutes during the first 6 hours) at 3000 m altitude
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sedentary condition at 3000 m altitude
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise condition at 3000 m altitude
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Exercise condition at 171 m altitude
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sedentary condition at 171 m altitude
Number of subjects: 8
Study: 8981304

Group type: EXPERIMENTAL
Intervention: rIFNA (9 x 10(6) IU) intramuscularly every other day for 6 months
Number of subjects: 20
Study: 1478293

Group type: EXPERIMENTAL
Intervention: Polyadenylic-polyuridylic acid (AU), one i.v. injection of 60 mg (in 50 ml of solution) once a week for 6 weeks
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo (P), one i.v. injection of 50 ml of saline solution with the same schedule
Number of subjects: 288

Group type: COMPARATOR
Intervention: Overall survival comparison between AU and P groups
Number of subjects: 288
Study: 6587756

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 3094463

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Sodium aurothiomalate
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (original group)
Number of subjects: 90
Study: 29690924

Group type: EXPERIMENTAL
Intervention: Regularly dosed paracetamol
Number of subjects: 0

Group type: COMPARATOR
Intervention: No paracetamol
Number of subjects: 0
Study: 26199465

Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine (DEX)
Number of subjects: 60
Study: 23893147

Group type: EXPERIMENTAL
Intervention: Intradiscal and intraforaminal injection of oxygen‐ozone
Number of subjects: 172

Group type: COMPARATOR
Intervention: Injection of oxygen‐ozone combined with 1ml of compound betamethasone
Number of subjects: 172
Study: 21912342

Group type: EXPERIMENTAL
Intervention: Mouthpiece use during exercise
Number of subjects: 28

Group type: COMPARATOR
Intervention: No mouthpiece during exercise
Number of subjects: 28
Study: 18829998

Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (150 mg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Verapamil (1 mg)
Number of subjects: 86
Study: 16773438

Group type: EXPERIMENTAL
Intervention: Supportive-expressive group therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 14604715

Group type: EXPERIMENTAL
Intervention: Microkeratome blades wiped with sterile 100% alcohol before LASIK
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group with microkeratome blades wiped with balanced salt solution (BSS)
Number of subjects: 24
Study: 10758928

Group type: EXPERIMENTAL
Intervention: 6Fr Techstar device
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: 8Fr or 10Fr Prostar-Plus device
Number of subjects: 715

Group type: COMPARATOR
Intervention: Traditional compression
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Suture-mediated closure
Number of subjects: 715
Study: 8742282

Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 28

Group type: COMPARATOR
Intervention: Intravenous regional anesthesia
Number of subjects: 28